Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$76.81

0.14 (0.18%)

12:05
11/21/16
11/21
12:05
11/21/16
12:05

Eli Lilly call volume above normal and directionally bullish

Bullish option flow detected in Eli Lilly with 9,794 calls trading, 1.6x expected, and implied vol increasing almost 2 points to 58.78%. Dec-16 77.5 calls and Dec-16 90 calls are the most active options, with total volume in those strikes near 6,000 contracts. The Put/Call Ratio is 0.33. Earnings are expected on January 31st.

  • 04

    Dec

LLY Eli Lilly
$76.81

0.14 (0.18%)

11/03/16
BMOC
11/03/16
NO CHANGE
BMOC
Eli Lilly factored pricing pressure into guidance, says BMO Capital
After meeting with Eli Lilly, BMO Capital analyst Alex Arfaei reports that the company seemed surprised at the intensity of investors' concerns about pricing pressure on it. The analyst says that the company anticipated pricing pressure and factored it into its guidance. The analyst keeps a $91 price target and an Outperform rating on the shares.
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
11/11/16
JEFF
11/11/16
NO CHANGE
Target $100
JEFF
Buy
Jefferies bullish on Lilly regardless of Alzheimer's data
Jefferies analyst Jeffrey Holford believes shares of Eli Lilly "can work over time" regardless of Alzheimer's disease drug solanezumab's Phase III study outcome. The analyst, however, says he has enough confidence to recommend Lilly shares ahead of the EXPEDITION3 data readout. Holford increased his base case solanezumab peak sales to $5B. He says Lilly remains one of his top picks with a Buy rating and $100 price target.
11/15/16
JPMS
11/15/16
NO CHANGE
Target $95
JPMS
Overweight
JPMorgan sees favorable risk/reward for Lilly into Alzheimer's data
JPMorgan analyst Chris Schott sees a favorable risk/reward profile for shares of Eli Lilly into the solanezumab data for Alzheimer's, which is expected by year-end. Favorable data from the EXPEDITION-3 trial would represent a catalyst not just for Lilly and other Alzheimer's associated names but for the biopharma space as a whole, Schott tells investors in a research note. The analyst expects 20%-plus share upside in the event the trial is successful on both primary and secondary endpoints. He assigns a 10%-20% probability to this outcome. Schott sees 10%-20% share upside for Lilly should the study hit on its primary but only shows a trend on secondary endpoints. He assigns a 50%-60% probability for this outcome. The analyst also sees a 10% move to the downside if the study fails both endpoints, an outcome he assigns a 20% probability. Schott reiterates an Overweight rating on Lilly with a $95 price target. He believes Lilly's "diverse range of pipeline opportunities" largely supports the valuation at current levels.

TODAY'S FREE FLY STORIES

TEAM

Atlassian

$55.60

0.73 (1.33%)

06:03
01/19/18
01/19
06:03
01/19/18
06:03
Recommendations
Atlassian analyst commentary  »

Atlassian price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

STI

SunTrust

$67.94

-0.41 (-0.60%)

06:03
01/19/18
01/19
06:03
01/19/18
06:03
Earnings
SunTrust reports Q4 EPS with items $1.48, consensus $1.05 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

RF

Regions Financial

$18.15

-0.21 (-1.14%)

06:02
01/19/18
01/19
06:02
01/19/18
06:02
Hot Stocks
Breaking Hot Stocks news story on Regions Financial »

Regions Financial reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

RF

Regions Financial

$18.15

-0.21 (-1.14%)

06:02
01/19/18
01/19
06:02
01/19/18
06:02
Hot Stocks
Regions Financial reports Q4 net interest margin 3.32% »

Up 18 basis points, and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

RF

Regions Financial

$18.15

-0.21 (-1.14%)

06:00
01/19/18
01/19
06:00
01/19/18
06:00
Earnings
Regions Financial reports Q4 cont ops EPS 27c, consensus 26c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

MWA

Mueller Water

$12.28

-0.06 (-0.49%)

05:59
01/19/18
01/19
05:59
01/19/18
05:59
Downgrade
Mueller Water rating change  »

Cowen downgrades Mueller…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

  • 22

    Feb

OBLN

Obalon Therapeutics

$6.14

-0.725 (-10.56%)

05:57
01/19/18
01/19
05:57
01/19/18
05:57
Syndicate
Obalon Therapeutics 5.455M share Secondary priced at $5.50 »

UBS, Canaccord and Stifel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 19

    Jan

GDEN

Golden Entertainment

$28.21

-0.6 (-2.08%)

05:56
01/19/18
01/19
05:56
01/19/18
05:56
Syndicate
Golden Entertainment 6.5M share Secondary priced at $28.00 »

JPMorgan and Morgan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

AGIO

Agios Pharmaceuticals

$68.15

-2.18 (-3.10%)

05:56
01/19/18
01/19
05:56
01/19/18
05:56
Syndicate
Agios Pharmaceuticals 7.09M share Secondary priced at $67.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 19

    Jan

AAPL

Apple

$179.26

0.16 (0.09%)

05:55
01/19/18
01/19
05:55
01/19/18
05:55
Periodicals
S. Korean consumer group files criminal complaint against Apple CEO, CNBC says »

South Korean consumer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

AVT

Avnet

$41.32

-0.33 (-0.79%)

05:54
01/19/18
01/19
05:54
01/19/18
05:54
Upgrade
Avnet rating change  »

Avnet upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

FCAU

Fiat Chrysler

$23.40

0.28 (1.21%)

05:54
01/19/18
01/19
05:54
01/19/18
05:54
Upgrade
Fiat Chrysler rating change  »

Fiat Chrysler upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DANOY

Danone

$17.06

0.085 (0.50%)

05:54
01/19/18
01/19
05:54
01/19/18
05:54
Upgrade
Danone rating change  »

Danone upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WNS

WNS Holdings

$45.28

2.31 (5.38%)

05:53
01/19/18
01/19
05:53
01/19/18
05:53
Downgrade
WNS Holdings rating change  »

WNS Holdings downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BK

BNY Mellon

$55.35

-2.54 (-4.39%)

05:53
01/19/18
01/19
05:53
01/19/18
05:53
Upgrade
BNY Mellon rating change  »

BNY Mellon upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

CRBP

Corbus Pharmaceuticals

$7.95

-0.25 (-3.05%)

05:52
01/19/18
01/19
05:52
01/19/18
05:52
Initiation
Corbus Pharmaceuticals initiated  »

Corbus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESS

Essex Property Trust

$224.60

-2.76 (-1.21%)

05:49
01/19/18
01/19
05:49
01/19/18
05:49
Downgrade
Essex Property Trust rating change  »

Essex Property Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

GPN

Global Payments

, FDC

First Data

$17.56

-0.04 (-0.23%)

05:48
01/19/18
01/19
05:48
01/19/18
05:48
Recommendations
Global Payments, First Data, Worldpay analyst commentary  »

Global Payments price…

GPN

Global Payments

FDC

First Data

$17.56

-0.04 (-0.23%)

WP

Worldpay

$79.08

1.19 (1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

  • 01

    Mar

MWA

Mueller Water

$12.28

-0.06 (-0.49%)

05:48
01/19/18
01/19
05:48
01/19/18
05:48
Downgrade
Mueller Water rating change  »

Mueller Water downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

  • 22

    Feb

CUB

Cubic

$59.95

-0.8 (-1.32%)

05:48
01/19/18
01/19
05:48
01/19/18
05:48
Downgrade
Cubic rating change  »

Cubic downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jun

VEOEY

Veolia Environment

$25.50

-0.285 (-1.11%)

05:46
01/19/18
01/19
05:46
01/19/18
05:46
Upgrade
Veolia Environment rating change  »

Veolia Environment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAA

MAA

$91.54

-1.33 (-1.43%)

05:45
01/19/18
01/19
05:45
01/19/18
05:45
Upgrade
MAA rating change  »

MAA upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

SIEN

Sientra

$10.33

-0.71 (-6.43%)

05:45
01/19/18
01/19
05:45
01/19/18
05:45
Upgrade
Sientra rating change  »

Sientra upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

CMG

Chipotle

$337.53

2.9 (0.87%)

05:43
01/19/18
01/19
05:43
01/19/18
05:43
Upgrade
Chipotle rating change  »

Chipotle upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

PLYA

Playa Hotels & Resorts

$10.75

-0.56 (-4.95%)

05:42
01/19/18
01/19
05:42
01/19/18
05:42
Recommendations
Playa Hotels & Resorts analyst commentary  »

Playa selloff yesterday a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.